This appears to be a very interesting dual acting agonist combination. I would like to see the relative potencies and data. Preclinical evidence suggests high efficacy, when combining the gut-derived hormone GLP-1 with FGF21. I could not find any USPTO filings using either agonist names along with 'Yuhan Corporation' in a quick look.